UCB SA (LON: 0NZT)

London flag London · Delayed Price · Currency is GBP · Price in EUR
183.23
-0.92 (-0.50%)
At close: Dec 20, 2024
140.50%
Market Cap 29.33B
Revenue (ttm) 4.62B
Net Income (ttm) 203.48M
Shares Out n/a
EPS (ttm) 1.04
PE Ratio 144.15
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,694
Open 183.88
Previous Close 184.16
Day's Range 179.80 - 186.60
52-Week Range 62.75 - 157.38
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 27, 2025

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1925
Employees 9,083
Stock Exchange London Stock Exchange
Ticker Symbol 0NZT
Full Company Profile

Financial Performance

In 2023, UCB SA's revenue was 5.18 billion, a decrease of -4.87% compared to the previous year's 5.45 billion. Earnings were 343.00 million, a decrease of -17.94%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.